Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Return on Sales (2018 - 2025)

Lipocine's Return on Sales history spans 8 years, with the latest figure at 27.81% for Q3 2025.

  • For Q3 2025, Return on Sales fell 2727.0% year-over-year to 27.81%; the TTM value through Sep 2025 reached 1.27%, down 73.0%, while the annual FY2024 figure was 0.0%, 574.0% up from the prior year.
  • Return on Sales reached 27.81% in Q3 2025 per LPCN's latest filing, down from 3.54% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 118.57% in Q2 2021 to a low of 219.28% in Q2 2023.
  • Average Return on Sales over 5 years is 14.77%, with a median of 2.13% recorded in 2023.
  • Peak YoY movement for Return on Sales: tumbled -21401bps in 2023, then surged 18501bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 0.78% in 2021, then crashed by -2842bps to 21.52% in 2022, then soared by 149bps to 10.56% in 2023, then plummeted by -95bps to 0.51% in 2024, then plummeted by -5549bps to 27.81% in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Return on Sales are 27.81% (Q3 2025), 3.54% (Q2 2025), and 19.87% (Q1 2025).